MASS vs. ALIM, PROF, OGI, TELO, ELEV, CGEN, XFOR, OPT, IVA, and OM
Should you be buying 908 Devices stock or one of its competitors? The main competitors of 908 Devices include Alimera Sciences (ALIM), Profound Medical (PROF), Organigram (OGI), Telomir Pharmaceuticals (TELO), Elevation Oncology (ELEV), Compugen (CGEN), X4 Pharmaceuticals (XFOR), Opthea (OPT), Inventiva (IVA), and Outset Medical (OM). These companies are all part of the "medical" sector.
908 Devices (NASDAQ:MASS) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, community ranking, institutional ownership, valuation, analyst recommendations, risk and media sentiment.
88.1% of 908 Devices shares are owned by institutional investors. Comparatively, 99.8% of Alimera Sciences shares are owned by institutional investors. 27.8% of 908 Devices shares are owned by company insiders. Comparatively, 31.4% of Alimera Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
908 Devices presently has a consensus target price of $14.00, indicating a potential upside of 94.71%. Alimera Sciences has a consensus target price of $7.50, indicating a potential upside of 129.36%. Given Alimera Sciences' higher probable upside, analysts clearly believe Alimera Sciences is more favorable than 908 Devices.
Alimera Sciences received 339 more outperform votes than 908 Devices when rated by MarketBeat users. However, 61.54% of users gave 908 Devices an outperform vote while only 57.63% of users gave Alimera Sciences an outperform vote.
Alimera Sciences has higher revenue and earnings than 908 Devices. 908 Devices is trading at a lower price-to-earnings ratio than Alimera Sciences, indicating that it is currently the more affordable of the two stocks.
Alimera Sciences has a net margin of -24.93% compared to 908 Devices' net margin of -68.57%. 908 Devices' return on equity of -20.87% beat Alimera Sciences' return on equity.
In the previous week, 908 Devices had 6 more articles in the media than Alimera Sciences. MarketBeat recorded 15 mentions for 908 Devices and 9 mentions for Alimera Sciences. 908 Devices' average media sentiment score of 0.95 beat Alimera Sciences' score of 0.36 indicating that 908 Devices is being referred to more favorably in the media.
908 Devices has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Alimera Sciences has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.
Summary
Alimera Sciences beats 908 Devices on 11 of the 17 factors compared between the two stocks.
Get 908 Devices News Delivered to You Automatically
Sign up to receive the latest news and ratings for MASS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MASS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
908 Devices Competitors List
Related Companies and Tools
